USP17L11: A Drug Target / Disease Biomarker (G100287178)
USP17L11: A Drug Target / Disease Biomarker
USP17L11 is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and liver. It is a member of the USP family of proteins, which are known for their role in cell signaling and division. USP17L11 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.
One of the key features of USP17L11 is its ability to interact with several different proteins, including the protein known as T-cell factor (TGF-β). TGF-β is a well-known cytokine that plays a critical role in cell signaling and growth, and is involved in the development and progression of many diseases, including cancer. USP17L11 has been shown to be able to physically interact with TGF-β, which suggests that it may be a useful target for drugs that are designed to inhibit TGF-β signaling.
Another potential mechanism by which USP17L11 may be involved in disease is its role in the regulation of cellular processes that are important for maintaining the structure and function of tissues. USP17L11 has been shown to be involved in the regulation of cell division, which is a critical process for the growth and development of tissues. It is also involved in the regulation of cell migration, which is important for the formation of tissues and organs during development. In addition, USP17L11 has been shown to be involved in the regulation of cell adhesion, which is important for the stickiness of cells to tissues and the formation of tissues during development.
These properties make USP17L11 a promising target for drugs that are designed to inhibit TGF-β signaling, as TGF-β is involved in many diseases that are characterized by the over-regulation of cell signaling. In addition, USP17L11 may also be a useful biomarker for diseases that are characterized by the over-expression of USP17L11.
Another potential mechanism by which USP17L11 may be involved in disease is its role in the regulation of cellular processes that are important for maintaining the structure and function of tissues. USP17L11 has been shown to be involved in the regulation of cell division, which is a critical process for the growth and development of tissues. It is also involved in the regulation of cell migration, which is important for the formation of tissues and organs during development. In addition, USP17L11 has been shown to be involved in the regulation of cell adhesion, which is important for the stickiness of cells to tissues and the formation of tissues during development.
These properties make USP17L11 a promising target for drugs that are designed to inhibit TGF-β signaling, as TGF-β is involved in many diseases that are characterized by the over-regulation of cell signaling. In addition, USP17L11 may also be a useful biomarker for diseases that are characterized by the over-expression of USP17L11.
In conclusion, USP17L11 is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its ability to interact with TGF-β and its role in the regulation of cellular processes that are important for maintaining the structure and function of tissues make it a promising target for drugs that are designed to inhibit TGF-β signaling. Further research is needed to determine the full extent of USP17L11's potential as a drug target or biomarker for diseases.
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 11
Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection
The "USP17L11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L11 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14
